Sometimes compounds provide inconclusive or conflicting clinical results in regard to efficacy and toxicity because individuals may react differently to a particular compound. Using state-of-the-art molecular biology combined with sophisticated automation and LC-MS detection, we utilize our gADME™ Program to assess the role of common genetic variants of drug metabolizing enzymes and transporters in clinical outcomes for a given drug compound. These technologies help evaluate the range of variable responses and can lead to the development of tests or other criteria to identify appropriate dosing for individuals, thereby making a compound safer and more effective.

• Genomic gADME™ Panel - Using a comprehensive panel of enzymatic assays containing all human drug metabolizing enzymes and transporters, enzymes capable of using the compound as a substrate are identified. Considerable effort has been made to ensure that the enzymes expressed represent the most common forms found in the human population. It can also be applied to preclinical and clinical stages in the selection of compounds with desired metabolic profiles, the prediction of drug-drug interactions, the acceleration of the identification of metabolite biotransformation steps and structure, and the synthesis of chemically refractory compounds.
• Genetic gADME™ Panel - After using our Genomic gADME™ Panel to identify the enzymes and transporters involved in the metabolism of a compound, we can evaluate the effect of common genetic polymorphisms by re-examining the activity using Gene Logic's panel of missense variant assays. By assessing the compound across the relevant genetic variants, the functional consequences of polymorphisms on the metabolism of a compound can be evaluated and the data can be used to generate genetically aware physiologically-based pharmacokinetic (PBPK) models that can suggest individual optimal dosing.